A Comprehensive Monograph on Pazopanib: Pharmacology, Clinical Efficacy, and Therapeutic Profile

I. Executive Summary

Pazopanib is an orally administered, second-generation, multi-targeted tyrosine kinase inhibitor (TKI) characterized by potent anti-angiogenic activity.[1] Developed by GlaxoSmithKline and now marketed by Novartis under the brand name Votrient®, it represents a significant therapeutic option in specific oncologic settings.[2] The primary mechanism of action involves the competitive inhibition of multiple receptor tyrosine kinases, most notably vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), platelet-derived growth factor receptors (PDGFR-α and -β), and the stem cell factor receptor (c-Kit).[2] This blockade disrupts downstream signaling pathways crucial for angiogenesis, tumor cell growth, and metastasis.

Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have granted marketing authorization for Pazopanib for the treatment of advanced Renal Cell Carcinoma (RCC) and for patients with advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy.[7] In RCC, its efficacy was established in a pivotal trial demonstrating a significant extension of progression-free survival (PFS) compared to placebo (median 9.2 vs. 4.2 months) and was later shown to be non-inferior to sunitinib, but with a more favorable quality-of-life profile.[11]

The clinical use of Pazopanib is governed by a complex pharmacokinetic profile, featuring low and variable bioavailability, pH-dependent absorption, and a significant food effect, which necessitate strict administration guidelines.[14] Critically, its safety profile is headlined by an FDA Boxed Warning for severe and potentially fatal hepatotoxicity, requiring rigorous liver function monitoring.[7] Other significant risks include hypertension, cardiac dysfunction, hemorrhagic and thrombotic events, and gastrointestinal perforation. Management of these adverse events often requires dose interruption or reduction. This monograph provides an exhaustive review of Pazopanib, synthesizing its chemical properties, pharmacological action, clinical trial evidence, and comprehensive safety profile to guide its optimal use in clinical practice.

II. Chemical Identity and Physicochemical Properties

A thorough understanding of Pazopanib's chemical and physical characteristics is fundamental to appreciating its formulation, pharmacokinetic behavior, and clinical handling. As a synthetic indazolylpyrimidine, it belongs to the chemical classes of indazoles, aminopyrimidines, and sulfonamides.[1]

Its molecular identity is defined by the systematic IUPAC name 5-({4-pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide.[2] The drug is most commonly known by its generic name, Pazopanib, and its International Nonproprietary Name (INN), Pazopanibum.[1] It is marketed globally under the brand name Votrient®.[2] During its development, it was referred to by research codes such as GW786034 and GW786034B.[3]

Pazopanib's physicochemical properties profoundly influence its clinical application. It exists as a white to off-white solid powder and is formulated for oral use as its hydrochloride salt.[5] A key characteristic is its pH-dependent solubility. It is slightly soluble at a very low pH of 1 but becomes practically insoluble in aqueous media at pH values of 4 and above.[14] This property is the primary driver of its complex absorption profile and leads to significant drug-drug and drug-food interactions. Because dissolution in the stomach's acidic environment is a prerequisite for absorption, any agent that increases gastric pH, such as proton pump inhibitors (PPIs) or H2-receptor antagonists, can severely diminish its bioavailability.[1] This direct causal link between a fundamental chemical property and a major clinical challenge underscores the stringent administration guidelines to take Pazopanib on an empty stomach and avoid co-administration with acid-reducing agents.[21] The compound is soluble in organic solvents like dimethyl sulfoxide (DMSO) and dimethylformamide (DMF).[5] For storage, it is stable at ambient temperatures for shipping but requires dry, dark conditions at 0-4°C for short-term and -20°C for long-term preservation.[5]

Table 1: Summary of Pazopanib Identifiers and Physicochemical Properties

Property	Value	Source(s)
Generic Name	Pazopanib	1
Brand Name	Votrient®	2
IUPAC Name	5-({4-pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide	2
CAS Number	444731-52-6 (free base)	4
DrugBank ID	DB06589	1
PubChem CID	11525740	2
Chemical Formula	$C_{21}H_{23}N_{7}O_{2}S$	4
Molecular Weight	437.52 g/mol	2
Appearance	White to off-white solid powder	5
Solubility	Soluble in DMSO; Practically insoluble in water at $pH \geq 4$	5

III. Pharmacology and Mechanism of Action

Pazopanib exerts its therapeutic effects through the targeted inhibition of specific signaling pathways that are fundamental to tumor growth and survival. Its classification as a potent, selective, second-generation multi-targeted receptor TKI distinguishes it from earlier, less selective agents.[1]

3.1. Multi-Targeted Tyrosine Kinase Inhibition

As a small molecule, Pazopanib is hydrophobic, allowing it to diffuse across the cell membrane into the cytoplasm. Once inside, it functions as a competitive inhibitor of adenosine triphosphate (ATP) at the ATP-binding site within the intracellular domain of various receptor tyrosine kinases.[6] By occupying this site, Pazopanib prevents the phosphorylation and subsequent activation of the receptor, thereby blocking the downstream intracellular signaling cascades that promote cell proliferation, survival, and angiogenesis.[6]

3.2. Primary Molecular Targets and Binding Affinity

The efficacy of Pazopanib is derived from its potent inhibitory activity against a specific constellation of kinases that are key drivers of tumorigenesis, particularly in highly vascularized cancers like RCC. Extensive cell-free enzyme assays have quantified its binding affinity, expressed as the half-maximal inhibitory concentration (IC50​), for its primary targets.[5]

• Vascular Endothelial Growth Factor Receptors (VEGFRs): Pazopanib is a potent inhibitor of the principal mediators of angiogenesis, with IC50​ values of 10 nM for VEGFR-1, 30 nM for VEGFR-2, and 47 nM for VEGFR-3.[5]
• Platelet-Derived Growth Factor Receptors (PDGFRs): It also targets receptors involved in cell growth, proliferation, and angiogenesis, with IC50​ values of 71 nM for PDGFR-α and 84 nM for PDGFR-β.[24]
• Stem Cell Factor Receptor (c-Kit): Inhibition of c-Kit, a receptor implicated in the pathogenesis of various malignancies, occurs with an IC50​ of 74 nM.[5]
• Other Kinase Targets: Pazopanib also demonstrates activity against other targets, including fibroblast growth factor receptor 1 (FGFR-1, IC50​ = 140 nM) and colony-stimulating factor 1 receptor (c-Fms, IC50​ = 146 nM).[5]

The relevance of these enzymatic activities has been confirmed in cell-based assays, which demonstrated that Pazopanib effectively inhibits the ligand-induced autophosphorylation of VEGFR-2, PDGFR-β, and c-Kit in relevant human cell lines.[14]

3.3. Pharmacodynamic Effects

The molecular inhibition of these key kinases translates into observable pharmacodynamic effects that constitute the drug's anti-tumor activity.

• Anti-angiogenesis: The predominant effect of Pazopanib is the potent inhibition of angiogenesis, the process of new blood vessel formation that is essential for supplying tumors with oxygen and nutrients.[2] By blocking VEGFR and PDGFR signaling, it effectively chokes off the tumor's blood supply.[6]
• Direct Anti-tumor Effects: In clinical settings, treatment with Pazopanib leads to a measurable reduction in tumor blood flow, an increase in tumor cell apoptosis, a direct inhibition of tumor growth, and a decrease in tumor interstitial fluid pressure.[1]
• Modulation of Cell Adhesion: Preclinical studies have also shown that Pazopanib can inhibit the VEGF-induced upregulation of the surface adhesion proteins ICAM-1 and VCAM-1. This action reduces the adhesion of multiple myeloma cells to endothelial cells, potentially interfering with metastatic processes.[24]

The specific pattern of kinase inhibition directly correlates with both the drug's therapeutic efficacy and its characteristic adverse effect profile. The potent blockade of VEGFR signaling is the cornerstone of its effectiveness in highly vascular tumors such as RCC.[27] However, these same receptors are vital for maintaining normal vascular homeostasis throughout the body. Consequently, systemic inhibition of this pathway leads to predictable "on-target" toxicities. For instance, hypertension, a very common side effect, is a well-documented consequence of VEGFR inhibition, which disrupts endothelial function and nitric oxide-mediated vasodilation.[2] Similarly, hemorrhagic events and impaired wound healing are linked to the compromised vascular integrity that results from sustained VEGFR blockade.[2] This establishes a direct and predictable link: the very mechanism that confers Pazopanib's anti-tumor activity is also the source of its most frequent and clinically significant side effects.

IV. Clinical Pharmacokinetics

The pharmacokinetic profile of Pazopanib is complex and is a critical factor in its clinical management. It is characterized by pH-dependent solubility, significant interpatient variability, and a non-linear, time-dependent bioavailability that presents notable challenges for achieving consistent therapeutic exposure.[14]

4.1. Absorption and Bioavailability

The absorption of Pazopanib following oral administration is slow, incomplete, and non-linear across a dose range of 50 mg to 2000 mg.[1] The mean absolute bioavailability is low, estimated to be 21.4%, with a wide range between individuals (13.5% to 38.9%).[29] After a single dose, the median time to reach maximum plasma concentration (

Tmax​) is 3.5 hours.[2]

Two factors profoundly impact absorption: food and tablet integrity.

• Food Effect: Administration with food significantly increases drug exposure. Compared to a fasted state, a high-fat meal increases the area under the curve (AUC) and maximum concentration (Cmax​) by approximately two-fold. A low-fat meal produces a similar, albeit slightly smaller, increase.[2] This large food effect necessitates a strict administration guideline of taking Pazopanib on an empty stomach (at least one hour before or two hours after a meal) to minimize pharmacokinetic variability and prevent unintended overexposure.[21]
• Formulation Effect: Studies have shown that administering Pazopanib as a crushed tablet increases the AUC by 1.46-fold and the Cmax​ by two-fold compared to swallowing the tablet whole.[2] This indicates that the rate of dissolution is a limiting step in its absorption. Consequently, the prescribing information explicitly warns against crushing or breaking the tablets to avoid an uncontrolled and potentially toxic increase in systemic exposure.[21]

4.2. Distribution

Once absorbed into the systemic circulation, Pazopanib is extensively bound to plasma proteins, with a bound fraction exceeding 99.5%.[1] It binds primarily to human serum albumin, with lesser binding to alpha-1 acid glycoprotein.[15] The steady-state volume of distribution (

Vd​) is small, approximately 11.1 L, which suggests that the drug is largely confined to the vascular compartment with limited distribution into peripheral tissues.[1]

4.3. Metabolism and Elimination

Pazopanib is primarily metabolized in the liver via the cytochrome P450 enzyme system. The major metabolic pathway is through CYP3A4, with minor contributions from CYP1A2 and CYP2C8.[1] The resulting metabolites, which include various hydroxylated and N-demethylated forms, are significantly less active than the parent compound (10- to 20-fold less potent) and account for less than 10% of the total drug-related material in plasma.[1] Therefore, Pazopanib itself is the principal active component in the circulation.

Elimination of Pazopanib and its metabolites occurs predominantly through the feces, which accounts for approximately 82% of an administered dose.[1] Renal excretion is a negligible pathway, with less than 4% of the dose recovered in the urine.[1] This route of elimination implies that dose adjustments are not required for patients with renal impairment.[20] The terminal elimination half-life (

t1/2​) is approximately 31 hours, which supports a once-daily dosing regimen and leads to drug accumulation with repeated administration.[2]

4.4. Exposure-Response Relationships

A critical aspect of Pazopanib's clinical pharmacology is the well-established relationship between systemic exposure and both efficacy and toxicity.[14] Clinical studies have identified a target steady-state trough plasma concentration (

Cmin​) of ≥20.5 mg/L (or µg/mL). Patients who achieve this threshold have been shown to have significantly longer progression-free survival and greater tumor shrinkage compared to those with lower concentrations.[14] Conversely, higher plasma concentrations are also correlated with an increased incidence and severity of toxicities, particularly hypertension.[14]

The drug's complex and highly variable pharmacokinetics present a significant clinical challenge. The combination of low bioavailability, a major food effect, pH-dependent absorption, and substantial inter-patient variability means that the standard 800 mg fixed dose results in a wide spectrum of plasma concentrations across the patient population. Some patients may achieve sub-therapeutic levels, limiting efficacy, while others may experience excessive exposure, increasing the risk of severe adverse events. This pharmacokinetic profile creates a strong scientific rationale for the implementation of Therapeutic Drug Monitoring (TDM). By measuring individual patient plasma levels, clinicians could potentially titrate the dose to achieve the target Cmin​ of ≥20.5 mg/L, thereby personalizing therapy to optimize the benefit-risk ratio for each patient.

Table 2: Key Pharmacokinetic Parameters of Pazopanib

Parameter	Value	Source(s)
Bioavailability (Absolute)	Mean: 21.4% (Range: 13.5% - 38.9%)	29
Time to Max. Concentration (Tmax​)	Median: 3.5 hours (Range: 1.0 - 11.9 hours)	2
Plasma Protein Binding	>99.5%	1
Volume of Distribution (Vd​)	11.1 L	1
Elimination Half-Life (t1/2​)	~31 hours	2
Primary Metabolism	$CYP3A4$ (major); $CYP1A2$, $CYP2C8$ (minor)	1
Primary Excretion	Feces (~82%); Urine (<4%)	1
Target Trough Concentration (Cmin​)	≥20.5 mg/L (µg/mL)	14

V. Clinical Efficacy in Approved Indications

The clinical utility of Pazopanib is firmly established through a series of robust clinical trials that have defined its role in the treatment of advanced Renal Cell Carcinoma and Soft Tissue Sarcoma.

5.1. Advanced Renal Cell Carcinoma (RCC)

Pazopanib is a standard first-line therapeutic option for patients with advanced or metastatic RCC.

5.1.1. First-Line Monotherapy and Pivotal Trials

The initial approval of Pazopanib was based on the VEG105192 trial, a landmark Phase 3, randomized, double-blind, placebo-controlled study.[11] This trial enrolled both treatment-naïve patients and those who had previously received cytokine therapy. The results were unequivocally positive, demonstrating that Pazopanib conferred a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS). The median PFS for patients in the Pazopanib arm was 9.2 months, more than double the 4.2 months observed in the placebo arm.[11]

To position Pazopanib within the existing therapeutic landscape, the COMPARZ trial was conducted. This was a large, randomized, open-label, Phase 3 non-inferiority trial that directly compared first-line Pazopanib with sunitinib, another standard-of-care TKI.[12] The study successfully met its primary endpoint, demonstrating that Pazopanib was non-inferior to sunitinib in terms of PFS.[12] However, the trial's significance extends beyond efficacy. The comprehensive collection of patient-reported outcomes revealed a crucial distinction: analyses of health-related quality of life (HRQoL) and overall patient preference significantly favored Pazopanib.[12] Patients treated with Pazopanib reported less fatigue and less hand-foot syndrome, two particularly burdensome side effects associated with sunitinib. This "differentiated tolerability profile" established that for therapies used in a palliative setting, the patient experience is a critical determinant of treatment choice, positioning Pazopanib as a preferred first-line option for many clinicians and patients.

5.1.2. Sequential Therapy and Real-World Evidence

The evolution of RCC treatment has increasingly involved sequential therapies. The PAZOREAL study, a prospective, non-interventional study, evaluated the real-world effectiveness of first-line Pazopanib followed by second-line nivolumab (an immune checkpoint inhibitor). The findings confirmed that this sequence is effective and well-tolerated, with a median overall survival (OS) of 32.6 months, supporting its use in clinical practice.[34] Furthermore, a Phase II trial (NCT03200717) specifically investigated Pazopanib's activity after progression on prior immune checkpoint inhibitor (ICI) therapy. This study demonstrated continued efficacy, with a median PFS of 7.5 months when used as a second-line agent and 4.6 months as a third-line agent, confirming its utility in the post-ICI setting.[35]

The PRINCIPAL study (NCT01649778), a large, global, observational study, provided further validation of Pazopanib's effectiveness outside the controlled environment of a clinical trial. In a real-world cohort of over 650 patients receiving first-line Pazopanib, the median PFS was 10.3 months and the median OS was 29.9 months, results that are highly consistent with the pivotal trial data and solidify its standing as a reliable first-line therapy.[32]

5.1.3. Adjuvant Therapy: A Negative Finding

In stark contrast to its success in the metastatic setting, Pazopanib failed as an adjuvant therapy. The ECOG-ACRIN E2810 trial was a randomized, double-blind, placebo-controlled Phase 3 study designed to test whether Pazopanib could prevent or delay recurrence in RCC patients with no evidence of disease (NED) following metastasectomy.[39] The trial did not meet its primary endpoint; Pazopanib did not significantly improve disease-free survival (DFS) compared to placebo. More alarmingly, the study revealed a concerning and statistically significant trend towards worse overall survival in the Pazopanib arm (HR 2.55 in favor of placebo).[39] This critical negative result strongly argues against the use of Pazopanib in the adjuvant setting and suggests that in the context of microscopic or absent disease, the drug's toxicities may outweigh any potential anti-tumor benefit, possibly leading to net harm.

5.2. Advanced Soft Tissue Sarcoma (STS)

Pazopanib is approved for the treatment of adult patients with specific subtypes of advanced STS who have received prior chemotherapy.[7]

5.2.1. Pivotal Trial and Indication Limitations

The approval for STS was based on the results of the PALETTE trial, a pivotal Phase 3, randomized, double-blind, placebo-controlled study.[8] This trial enrolled patients with metastatic non-adipocytic STS who had progressed on or after standard chemotherapy. The study demonstrated a statistically significant improvement in median PFS for patients treated with Pazopanib compared to placebo, establishing its efficacy in this heavily pre-treated population. Importantly, the trial did not show a benefit in patients with adipocytic STS or gastrointestinal stromal tumors (GIST), which led to a specific limitation of use in the drug's label.[7]

5.2.2. Combination with Chemotherapy and Radiotherapy

Research has explored integrating Pazopanib into multimodal treatment strategies for STS. An early-phase clinical trial involving both children and adults with high-risk, locally advanced STS investigated adding Pazopanib to standard neoadjuvant therapy (doxorubicin/ifosfamide chemotherapy plus radiation). The combination was found to be safe and resulted in a higher rate of pathological response (i.e., percentage of dead tumor cells in the surgical specimen) compared to standard therapy alone.[43] Similarly, the

PASART-2 trial combined neoadjuvant radiotherapy with Pazopanib in patients with high-risk, localized STS. While the study did not meet its ambitious primary endpoint of a 30% pathological complete response (pCR) rate, the observed 20% pCR was a notable improvement over historical rates with radiotherapy alone, and the regimen was generally well-tolerated.[44]

Table 3: Summary of Pivotal Clinical Trials for Approved Indications (RCC and STS)

Trial Name / ID	Phase	Indication	Comparison Arms	Primary Endpoint	Key Result	Source(s)
VEG105192	3	Advanced RCC	Pazopanib vs. Placebo	Progression-Free Survival (PFS)	Median PFS: 9.2 mo vs. 4.2 mo (HR 0.46)	11
COMPARZ	3	Advanced RCC	Pazopanib vs. Sunitinib	Progression-Free Survival (PFS)	Non-inferiority met (HR 1.05); HRQoL favored Pazopanib	12
PALETTE	3	Advanced STS	Pazopanib vs. Placebo	Progression-Free Survival (PFS)	Median PFS: 4.6 mo vs. 1.6 mo (HR 0.31)	8
E2810	3	Adjuvant RCC (Post-Metastasectomy)	Pazopanib vs. Placebo	Disease-Free Survival (DFS)	No significant improvement in DFS; OS favored placebo	39

VI. Investigational Applications and Future Directions

While firmly established in RCC and STS, research continues to explore Pazopanib's potential in other oncologic and non-oncologic conditions, as well as in novel therapeutic combinations.

6.1. Other Oncologic Indications

Early clinical studies have suggested that Pazopanib may have therapeutic properties in other malignancies. Initial data showed some activity in ovarian cancer, non-small cell lung cancer (NSCLC), and aggressive fibromatosis (desmoid tumors), although development for ovarian cancer was later discontinued by the manufacturer.[2] Clinical practice guidelines also note its potential off-label use in patients with progressive, metastatic

differentiated or medullary thyroid carcinoma who have failed prior standard therapies.[41]

6.2. Non-Oncologic Indications: Hereditary Hemorrhagic Telangiectasia (HHT)

One of the most promising areas of drug repurposing for Pazopanib is in the treatment of Hereditary Hemorrhagic Telangiectasia (HHT), a rare genetic disorder characterized by abnormal blood vessel formation, leading to severe, recurrent bleeding and chronic anemia. Based on its anti-angiogenic mechanism, off-label use of Pazopanib at very low doses (e.g., 50 mg/day) has shown remarkable positive effects, reducing the need for blood transfusions and decreasing the frequency of nose and gastrointestinal bleeding.[45]

The clinical development for this indication provides a compelling case study in the challenges of drug repurposing. An initial multi-center clinical trial was forced to close after the drug's ownership was transferred from GSK to a company not interested in pursuing the HHT indication.[45] In response, the patient advocacy organization Cure HHT, with significant funding from the U.S. Department of Defense (DOD) and the FDA, took the extraordinary step of commissioning the manufacture of a new, low-dose 25 mg capsule formulation of Pazopanib. This "new" formulation allowed for the launch of a formal clinical trial to establish safety and efficacy for HHT. The FDA has granted both Orphan Drug and Breakthrough Therapy designations for Pazopanib in HHT, recognizing its potential to be the first approved systemic therapy for this debilitating condition.[45]

6.3. Novel Combination Therapies

To enhance efficacy and overcome resistance, Pazopanib is being actively investigated in combination with other anti-cancer agents.

• With Other Targeted Agents: A retrospective analysis of several Phase 1 trials in sarcoma patients evaluated Pazopanib combined with inhibitors of histone deacetylase (HDAC) (vorinostat), mTOR (everolimus), Her2 (lapatinib/trastuzumab), or MEK. These combinations showed efficacy in refractory STS, with the Pazopanib-vorinostat combination appearing particularly promising.[46] The RENAVIV trial (NCT03592472) is a currently active, randomized Phase 3 study evaluating the combination of Pazopanib with the HDAC inhibitor abexinostat versus Pazopanib plus placebo in patients with advanced RCC.[47]
• With Other Anti-angiogenic Agents: A Phase 2 study in first-line clear cell RCC tested a regimen of alternating Pazopanib with bevacizumab (another anti-VEGF agent). The results were highly encouraging, with a clinical benefit rate of 78% and an overall response rate of 98%, suggesting a potent anti-angiogenic strategy for favorable-risk patients.[50]
• With Chemotherapy: A Phase 2 trial (NCT02357810) has explored the combination of Pazopanib with oral topotecan in patients with metastatic soft tissue and bone sarcomas, aiming to determine the progression-free rate at 12 weeks.[51]

VII. Safety Profile and Tolerability

The clinical use of Pazopanib is intrinsically linked to its significant and predictable safety profile. The adverse events are largely mechanism-based, arising from the systemic inhibition of key signaling pathways like VEGFR. Proactive monitoring and management are essential for its safe administration.

7.1. FDA Boxed Warning: Hepatotoxicity

The most serious risk associated with Pazopanib is hepatotoxicity, which is highlighted in an FDA Boxed Warning.[7] Severe and fatal cases of liver failure have been observed in clinical trials. This toxicity typically manifests as elevations in serum transaminases (ALT, AST) and bilirubin.[7] To mitigate this risk, strict monitoring of liver function tests (LFTs) is mandatory. LFTs must be measured at baseline, then at weeks 3, 5, 7, and 9 of treatment, followed by monitoring at months 3 and 4, and periodically thereafter as clinically indicated.[16] The prescribing information provides detailed algorithms for dose interruption, reduction, or permanent discontinuation based on the magnitude and nature of LFT elevations.[7]

7.2. Common and Serious Adverse Reactions

The spectrum of adverse drug reactions (ADRs) is broad, with many being common and generally manageable, while others are serious and potentially life-threatening.

7.2.1. Common Adverse Reactions (Occurring in ≥20% of patients)

• Gastrointestinal: Diarrhea is the most frequent side effect, affecting approximately half of all patients. Nausea, vomiting, abdominal pain, and dysgeusia (altered taste) are also very common.[2]
• Constitutional: Fatigue, anorexia (decreased appetite), and weight loss are frequently reported.[2]
• Cardiovascular: Hypertension is a very common on-target effect of VEGFR inhibition and often occurs early in the course of treatment.[2]
• Dermatologic: Changes in hair color (depigmentation) are a characteristic side effect. Skin rash, alopecia (hair loss), and skin hypopigmentation also occur frequently.[2]

7.2.2. Serious Warnings and Precautions

Beyond hepatotoxicity, the label includes numerous warnings for serious adverse events:

• Cardiac Dysfunction: Pazopanib can cause QT interval prolongation and torsades de pointes. It has also been associated with decreased left ventricular ejection fraction (LVEF) and congestive heart failure. Baseline and periodic monitoring of ECGs and serum electrolytes (calcium, magnesium, potassium) is recommended.[2]
• Hemorrhagic Events: Fatal hemorrhagic events (pulmonary, gastrointestinal, cerebral) have been reported. The drug should not be used in patients with a recent history of clinically significant hemorrhage.[7]
• Thrombotic Events: Both arterial (myocardial infarction, stroke) and venous (deep vein thrombosis, pulmonary embolism) thromboembolic events have occurred, some of which were fatal.[2]
• Gastrointestinal Perforation and Fistula: These have been reported, with some fatal outcomes. Caution is advised in patients at risk for these complications.[16]
• Thrombotic Microangiopathy (TMA): Rare but serious cases of TMA, including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), have been observed. The drug must be permanently discontinued if TMA occurs.[2]
• Reversible Posterior Leukoencephalopathy Syndrome (RPLS): This is a rare neurological disorder that can be fatal. Pazopanib should be permanently discontinued in any patient who develops RPLS.[7]
• Other Clinically Important Risks: Other notable risks include interstitial lung disease (ILD)/pneumonitis (can be fatal), impaired wound healing (therapy should be held before surgery), hypothyroidism (requires thyroid function monitoring), proteinuria leading to nephrotic syndrome, and tumor lysis syndrome.[7]

Table 4: Selected Adverse Drug Reactions by Frequency and System Organ Class

System Organ Class	Frequency	Adverse Reaction	Source(s)
Gastrointestinal Disorders	Very Common	Diarrhea, Nausea, Vomiting, Abdominal pain, Stomatitis	2
	Common	Dyspepsia	21
	Uncommon	Gastrointestinal perforation, Fistula	16
General Disorders	Very Common	Fatigue, Anorexia, Decreased weight	14
Vascular Disorders	Very Common	Hypertension	2
	Common	Hemorrhagic events	7
	Uncommon	Arterial/Venous Thromboembolic Events, Hypertensive Crisis	16
Skin/Subcutaneous Tissue	Very Common	Hair color change, Skin hypopigmentation, Exfoliative rash	42
	Common	Alopecia, Dry skin, Palmar-plantar erythrodysesthesia	21
Hepatobiliary Disorders	Very Common	Increased ALT, Increased AST	7
	Common	Increased bilirubin, Abnormal hepatic function	7
	Rare	Hepatic failure (including fatal)	21
Cardiac Disorders	Common	QT Prolongation, Cardiac dysfunction (decreased LVEF)	2
	Uncommon	Myocardial infarction, Torsades de pointes	21
Nervous System Disorders	Very Common	Dysgeusia, Headache	10
	Uncommon	Reversible Posterior Leukoencephalopathy Syndrome (RPLS)	7

VIII. Dosing, Administration, and Drug Interactions

The effective and safe use of Pazopanib requires strict adherence to specific guidelines for dosing, administration, dose modification, and management of drug interactions.

8.1. Formulations and Recommended Dosing

Pazopanib is supplied as film-coated tablets in strengths of 200 mg and 400 mg.[7]

• Recommended Dose: The standard starting dose for both advanced RCC and advanced STS is 800 mg orally once daily.[7] The total daily dose should not exceed 800 mg.
• Administration Instructions: Due to the significant food effect on absorption, Pazopanib must be taken on an empty stomach, defined as at least one hour before or two hours after a meal.[21] To ensure predictable bioavailability, the tablets must be swallowed whole with water and should not be broken or crushed.[21] If a patient misses a dose, it should be skipped entirely if the next scheduled dose is less than 12 hours away; patients should not take a double dose.[21]

8.2. Dose Modifications and Management

Dose adjustments are a critical component of managing Pazopanib-related toxicities and are also required for patients with hepatic impairment.

• For Adverse Reactions: Dose modifications should be made in 200 mg increments based on individual tolerability.[28] The specific dose reduction steps differ by indication:
• For RCC: The first dose reduction is to 400 mg once daily. A subsequent reduction to 200 mg once daily may be made if necessary. If the 200 mg dose is not tolerated, the drug should be permanently discontinued.[20]
• For STS: The first dose reduction is to 600 mg once daily, followed by a second reduction to 400 mg once daily. If the 400 mg dose is not tolerated, the drug should be permanently discontinued.[20]
• For Hepatic Impairment:
• Mild Impairment (Normal bilirubin with any ALT elevation, or bilirubin <1.5x ULN): No dose adjustment is necessary.[20]
• Moderate Impairment (Bilirubin >1.5 to 3x ULN): The dose must be reduced to 200 mg once daily.[20]
• Severe Impairment (Bilirubin >3x ULN): Pazopanib is not recommended for use in these patients.[20]
• For Renal Impairment: As renal excretion is minimal, no dose adjustment is required for any degree of renal impairment.[20]

8.3. Clinically Significant Drug-Drug and Drug-Food Interactions

Pazopanib is a substrate and inhibitor of several key metabolic enzymes and transporters, leading to a high potential for clinically significant interactions.

• Inhibitors of $CYP3A4$: Strong $CYP3A4$ inhibitors (e.g., ketoconazole, ritonavir, clarithromycin, itraconazole) can significantly increase Pazopanib plasma concentrations, raising the risk of toxicity. Concomitant use should be avoided. If co-administration is unavoidable, the Pazopanib dose should be reduced to 400 mg once daily.[7]
• Inducers of $CYP3A4$: Strong $CYP3A4$ inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort) can significantly decrease Pazopanib plasma concentrations, potentially compromising efficacy. Concomitant use should be avoided.[7]
• Drugs that Raise Gastric pH: Due to Pazopanib's pH-dependent solubility, agents that increase gastric pH can drastically reduce its absorption. Concomitant use of proton pump inhibitors (PPIs) and H2-receptor antagonists should be avoided. If an acid-reducing agent is necessary, a short-acting antacid may be considered, but its administration must be separated from the Pazopanib dose by several hours.[1]
• Drug-Food Interactions: In addition to avoiding administration with meals, patients should be instructed to avoid grapefruit and grapefruit juice, as they are known inhibitors of $CYP3A4$ and can increase Pazopanib exposure.[16]
• Pazopanib as an Inhibitor: Pazopanib itself is an inhibitor of $CYP3A4$, $CYP2D6$, and $CYP2C8$. Therefore, it can increase the concentrations of other drugs that are substrates of these enzymes. Caution is advised, and co-administration with substrates that have a narrow therapeutic index is not recommended.[4] For example, concomitant use with simvastatin (a $CYP3A4$ substrate) increases the risk of ALT elevations and should be approached with caution or avoided.[7]

Table 5: Guidelines for Dose Modification in Response to Key Adverse Events

Adverse Event	Grade / Severity	Recommended Action	Source(s)
Hepatotoxicity	ALT >3x to 8x ULN (isolated)	Continue Pazopanib; monitor LFTs weekly until resolution to Grade 1/baseline.	20
	ALT >8x ULN (isolated)	Withhold Pazopanib. May reintroduce at reduced dose (≤400 mg/day) if benefit outweighs risk.	20
	ALT >3x ULN with Bilirubin >2x ULN	Permanently discontinue Pazopanib.	7
Hypertension	Grade 3 (e.g., SBP >160 or DBP >100)	Withhold Pazopanib. Resume at reduced dose once controlled.	20
	Grade 4 / Hypertensive Crisis	Permanently discontinue Pazopanib.	20
Hemorrhage	Grade 2	Withhold Pazopanib. Resume at reduced dose upon resolution.	20
	Grade 3 or 4	Permanently discontinue Pazopanib.	20
Proteinuria	24-hr urine protein ≥3 grams	Withhold Pazopanib. Resume at reduced dose upon resolution. Discontinue if it recurs.	20
	Nephrotic Syndrome	Permanently discontinue Pazopanib.	20

IX. Regulatory History and Status

Pazopanib's path to becoming a standard therapy was marked by key approvals from major global regulatory bodies based on robust clinical trial data.

9.1. Key U.S. Food and Drug Administration (FDA) Approvals

• October 19, 2009: Pazopanib received its initial FDA approval for the treatment of patients with advanced Renal Cell Carcinoma (RCC).[1] This approval was primarily based on the strength of the data from the pivotal Phase 3 VEG105192 trial, which demonstrated a significant PFS advantage over placebo.[11]
• April 26, 2012: The FDA expanded Pazopanib's label to include the treatment of patients with advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy.[8] This decision was supported by the results of the PALETTE trial, which showed a clear PFS benefit in this patient population.[8]

9.2. Key European Medicines Agency (EMA) Approvals

• June 14, 2010: The European Commission granted a conditional marketing authorization for Pazopanib for the first-line treatment of advanced RCC and for patients who had received prior cytokine therapy.[2] The conditional status reflected the need for further comparative data.
• August 2012: Marketing authorization was granted for the treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who had received prior chemotherapy or had progressed within 12 months of (neo)adjuvant therapy.[42]
• June 14, 2013: The EMA converted the conditional approval for RCC to a full marketing authorization.[9] This upgrade was based on the review of the results from the COMPARZ trial, which demonstrated Pazopanib's non-inferiority to sunitinib and provided crucial data on its differentiated tolerability profile.[12]

9.3. Post-Marketing Developments

Following its initial approvals, the regulatory landscape for Pazopanib has continued to evolve. The FDA has issued product-specific guidance to facilitate the development of generic versions of Pazopanib hydrochloride, aiming to increase drug availability.[58] In December 2024, the FDA approved a new 200 mg tablet formulation from Aurobindo Pharma, which was shown to be bioequivalent and therapeutically equivalent to the reference product, Votrient®.[59]

X. Synthesis and Concluding Remarks

Pazopanib has solidified its position as a cornerstone therapy in the management of advanced Renal Cell Carcinoma and select subtypes of advanced Soft Tissue Sarcoma. Its clinical value is rooted in its potent, multi-targeted inhibition of key angiogenic and oncogenic pathways, primarily mediated through VEGFR, PDGFR, and c-Kit. This mechanism translates into a clear and consistent benefit in progression-free survival for its approved indications. In RCC, its non-inferior efficacy to sunitinib, coupled with a superior health-related quality-of-life profile, makes it a compelling first-line choice for many patients.

However, the therapeutic benefits of Pazopanib are balanced by a significant and predictable safety profile. The on-target nature of its mechanism is a double-edged sword, giving rise to both its efficacy and its most common and serious toxicities. The FDA Boxed Warning for severe hepatotoxicity, along with substantial risks of hypertension, cardiac dysfunction, hemorrhage, and thrombosis, mandates a vigilant approach to patient management. Successful therapy hinges on proactive monitoring, patient education, and the judicious use of dose modifications to maintain the delicate equilibrium between anti-tumor activity and tolerable toxicity.

The central challenge in optimizing Pazopanib therapy lies in its complex and highly variable pharmacokinetics. The standard 800 mg fixed dose is a blunt instrument in the face of low bioavailability, pH-dependent absorption, and a significant food effect. The established exposure-response relationship, where a plasma trough concentration of ≥20.5 mg/L is linked to better outcomes, provides a compelling rationale for a more personalized approach.

Future research must address several critical areas:

1. Therapeutic Drug Monitoring (TDM): Prospective, randomized trials are urgently needed to determine if a TDM-guided dosing strategy can improve the therapeutic index of Pazopanib by ensuring more patients achieve the target exposure while minimizing toxicity.
2. Understanding Adjuvant Failure: The detrimental overall survival trend observed in the post-metastasectomy E2810 trial is a major negative finding that requires further investigation. Understanding the biological mechanisms of potential harm in the microscopic disease setting is crucial for the entire class of VEGFR inhibitors.
3. Rational Combination Therapies: Overcoming acquired resistance remains a major hurdle. Continued investigation into rational combinations with immune checkpoint inhibitors, HDAC inhibitors, and other targeted agents is essential for improving long-term outcomes.
4. Drug Repurposing: The ongoing clinical trial in Hereditary Hemorrhagic Telangiectasia represents a landmark effort in patient-driven drug repurposing. Its success could provide the first approved systemic therapy for this rare disease and serve as a model for future endeavors.

In conclusion, Pazopanib is an effective and important agent in the modern oncology armamentarium. Its successful application demands a sophisticated understanding of its pharmacology, a proactive strategy for managing its mechanism-based toxicities, and careful patient selection. The future of Pazopanib therapy will likely be defined by a shift towards greater personalization, leveraging TDM and intelligent combination strategies to maximize its benefit for the individual patient.

Works cited

1. Pazopanib: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed July 15, 2025, https://go.drugbank.com/drugs/DB06589
2. Pazopanib - Wikipedia, accessed July 15, 2025, https://en.wikipedia.org/wiki/Pazopanib
3. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas - PubMed, accessed July 15, 2025, https://pubmed.ncbi.nlm.nih.gov/22112314/
4. Pazopanib | C21H23N7O2S | CID 10113978 - PubChem, accessed July 15, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/10113978
5. Pazopanib | GW786034 | CAS# 444731-52-6 (free base) | protein tyrosine kinase inhibitor, accessed July 15, 2025, https://www.medkoo.com/products/4714
6. Pazopanib: Approval for Soft-Tissue Sarcoma - PMC, accessed July 15, 2025, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093375/
7. VOTRIENT (pazopanib) tablets Label - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022465s-010S-012lbl.pdf
8. Pazopanib: Approval for Soft-Tissue Sarcoma - PMC, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4093375/
9. Votrient | European Medicines Agency (EMA), accessed July 15, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/votrient
10. Votrient, INN-pazopanib - EMA, accessed July 15, 2025, https://www.ema.europa.eu/en/documents/product-information/votrient-epar-product-information_en.pdf
11. FDA Approves Pazopanib for Kidney Cancer - Medscape, accessed July 15, 2025, https://www.medscape.com/viewarticle/711074
12. EMA lifts conditional status for GSK's Votrient® (pazopanib) and grants full approval, accessed July 15, 2025, https://www.fiercepharma.com/pharma/ema-lifts-conditional-status-for-gsk-s-votrient%C2%AE-pazopanib-and-grants-full-approval
13. The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use - PubMed, accessed July 15, 2025, https://pubmed.ncbi.nlm.nih.gov/21976546/
14. Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing - PMC, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5563343/
15. Pazopanib Pathway, Pharmacokinetics - PharmGKB, accessed July 15, 2025, https://www.pharmgkb.org/pathway/PA166163407
16. This label may not be the latest approved by FDA. For current ..., accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022465s028lbl.pdf
17. Pazopanib | C21H23N7O2S - ChemSpider, accessed July 15, 2025, https://www.chemspider.com/Chemical-Structure.8289501.html
18. Pazopanib | CAS 444731-52-6 | Tyrosine kinase inhibitor - StressMarq Biosciences Inc., accessed July 15, 2025, https://www.stressmarq.com/products/small-molecules/inhibitor/pazopanib-sih-506/
19. Chemical structure of pazopanib [Harris et al. 2008]. Molecular formula - ResearchGate, accessed July 15, 2025, https://www.researchgate.net/figure/Chemical-structure-of-pazopanib-Harris-et-al-2008-Molecular-formula_fig1_257251156
20. Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more, accessed July 15, 2025, https://reference.medscape.com/drug/votrient-pazopanib-999306
21. NEW ZEALAND DATA SHEET 1. PRODUCT NAME 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 3. PHARMACEUTICAL FORM 4. CLINICAL PARTICULAR - Medsafe, accessed July 15, 2025, https://www.medsafe.govt.nz/profs/datasheet/p/PazopanibTab.pdf
22. What is the administration route of pazopanib (Votrient)? - Dr.Oracle AI Medical Assistant, accessed July 15, 2025, https://www.droracle.ai/articles/56749/how-is-pazopanib-administered
23. Pazopanib Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 15, 2025, https://www.drugs.com/dosage/pazopanib.html
24. Pazopanib (free base) | CAS 444731-52-6 - AdipoGen Lif Sciences - Multi-targeted tyrosine kinase inhibitor, accessed July 15, 2025, https://adipogen.com/ag-cr1-3746-pazopanib-free-base.html
25. Pazopanib (GSK-VEG10003, GW786034B, CAS Number: 444731-52-6) | Cayman Chemical, accessed July 15, 2025, https://www.caymanchem.com/product/12097/pazopanib
26. pubmed.ncbi.nlm.nih.gov, accessed July 15, 2025, https://pubmed.ncbi.nlm.nih.gov/21395357/#:~:text=The%20primary%20mechanism%20of%20action,platelet%2Dderived%20growth%20factor%20receptor.
27. Drug review: Pazopanib | Japanese Journal of Clinical Oncology - Oxford Academic, accessed July 15, 2025, https://academic.oup.com/jjco/article/48/6/503/4978098
28. Votrient, pazopanib, accessed July 15, 2025, https://ec.europa.eu/health/documents/community-register/2012/20120803123573/anx_123573_en.pdf
29. Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib ..., accessed July 15, 2025, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563343/
30. Votrient (pazopanib) - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf
31. CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_clinpharmr.pdf
32. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study) - PubMed Central, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6459236/
33. The European Medicines Agency (EMA) Review Of Pazopanib (Votrient) For The Treatment Of Advanced Renal Cell Carcinoma (RCC) - AACR Journals, accessed July 15, 2025, https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-11-1734/84640/am/The-European-Medicines-Agency-EMA-Review-Of
34. Sequential treatment with pazopanib followed by nivolumab in patients with renal cell carcinoma: Updated interim results of the non-interventional study PAZOREAL. - ASCO, accessed July 15, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT299611
35. Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment | ClinicalTrials.gov, accessed July 15, 2025, https://www.clinicaltrials.gov/study/NCT03200717?term=AREA%5BConditionSearch%5D(%22Carcinoma,%20Renal%20Cell%22)&rank=2
36. Clinical Trial Results Summary - novctrd.com, accessed July 15, 2025, https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=1110
37. Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment | ClinicalTrials.gov, accessed July 15, 2025, https://clinicaltrials.gov/study/NCT03200717
38. Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma | ClinicalTrials.gov, accessed July 15, 2025, https://clinicaltrials.gov/study/NCT01649778
39. Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: ECOG-ACRIN E2810 - PMC, accessed July 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11514296/
40. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810 - ASCO Publications, accessed July 15, 2025, https://ascopubs.org/doi/abs/10.1200/JCO.23.01544
41. Votrient® (pazopanib tablets) Food and Drug Administration (FDA)-Approved Indications 1) Advanced Renal Cell Carcinoma (RCC). - Medical Mutual, accessed July 15, 2025, https://www.medmutual.com/-/media/MedMutual/Files/Providers/Prior-Auth-Rx/Votrient.pdf
42. European Commission grants marketing authorisation for pazopanib (Votrient®) in the treatment of certain advanced soft tissue sarcoma subtypes | GSK, accessed July 15, 2025, https://www.gsk.com/en-gb/media/press-releases/european-commission-grants-marketing-authorisation-for-pazopanib-votrient-in-the-treatment-of-certain-advanced-soft-tissue-sarcoma-subtypes/
43. Pazopanib Shows Promise for Children, Adults with Soft Tissue Sarcomas, accessed July 15, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2020/pazopanib-votrient-soft-tissue-sarcoma-children-adults
44. A phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma | Acta Oncologica, accessed July 15, 2025, https://medicaljournalssweden.se/actaoncologica/article/view/23872
45. Pazopanib Clinical Trial: Q&A - CureHHT, accessed July 15, 2025, https://curehht.org/paz-qa/
46. Outcomes of patients with advanced sarcoma enrolled in clinical trials of pazopanib in combination with histone deacetylase, mTOR, Her2, or MEK inhibitors. - ASCO Publications, accessed July 15, 2025, https://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.11057
47. Clinical Trials Using Pazopanib Hydrochloride - NCI, accessed July 15, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/pazopanib-hydrochloride
48. Clinical Trials Using Pazopanib Hydrochloride - NCI, accessed July 15, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/pazopanib-hydrochloride?pn=1
49. A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | ClinicalTrials.gov, accessed July 15, 2025, https://clinicaltrials.gov/study/NCT03592472
50. Pazopanib plus bevacizumab shows promise as a first-line treatment for kidney cancer, accessed July 15, 2025, https://actionkidneycancer.org/pazopanib-plus-bevacizumab-shows-promise-as-a-first-line-treatment-for-kidney-cancer/
51. Clinical Trial: NCT02357810 - My Cancer Genome, accessed July 15, 2025, https://www.mycancergenome.org/content/clinical_trials/NCT02357810/
52. Pazopanib (Votrient) - Cancer Research UK, accessed July 15, 2025, https://www.cancerresearchuk.org/about-cancer/treatment/drugs/pazopanib-votrient
53. 1 - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022465s021lbl.pdf
54. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VOTRIENT safely and effe - Novartis, accessed July 15, 2025, https://www.novartis.com/us-en/sites/novartis_us/files/votrient.pdf
55. Pazopanib - SWAG Cancer Alliance, accessed July 15, 2025, https://www.swagcanceralliance.nhs.uk/wp-content/uploads/2020/09/Pazopanib.pdf
56. Pazopanib (oral route) - Mayo Clinic, accessed July 15, 2025, https://www.mayoclinic.org/drugs-supplements/pazopanib-oral-route/description/drg-20073458
57. Votrient (pazopanib) FDA Approval History - Drugs.com, accessed July 15, 2025, https://www.drugs.com/history/votrient.html
58. Draft Guidance on Pazopanib Hydrochloride March 2021 - accessdata.fda.gov, accessed July 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022465.pdf
59. FDA Approves New Formulation of Pazopanib Tablets in RCC, Sarcoma - CancerNetwork, accessed July 15, 2025, https://www.cancernetwork.com/view/fda-approves-new-formulation-of-pazopanib-tablets-in-rcc-sarcoma